Coformulation would be Zan + Carfilzomib in one single drug. We don't have that patent, nor do we have that product.
RAC has submitted synergy patents (not coformulation) for at least 15 different drug synergies (I might have missed some).
Note that this announcement is the progression (cell - > mouse) of the work announced in 2021.
https://raceoncology.com/expanded-heart-protection-discovery-for-zantrene/
What's interesting is statements like these:
Strongly implies an update to Doan et al that was published in February re Zan's impact on HCM viability, broadly.
https://www.sciencedirect.com/science/article/pii/S144395062400043X
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-13
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
0.015(0.92%) |
Mkt cap ! $278.6M | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.64 | $1.62 | $26.01K | 16.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5023 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 400 | 1 |
View Market Depth
| Last trade - 14.02pm 11/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |